HanchorBio Inc., a global biotechnology company dedicated to developing innovative immuno-biomedicines to address significant unmet medical needs in oncology and autoimmune diseases, today announced the successful completion of its 5th semi-annual Scientific Advisory Board (SAB) meeting recently held in Taipei, Taiwan. The meeting brought together globally renowned scientific and clinical experts to provide strategic guidance to HanchorBio’s current preclinical and clinical R&D efforts and future development plans for advancing novel multi-functional biologics to treat cancer and autoimmune diseases.
Focusing on the latest scientific findings and industry trends in cancer therapeutic innovations, the SAB meeting provided valuable insights and recommendations to refine the company’s scientific and clinical strategies and advance its mission to deliver transformative therapies to human diseases with significant unmet needs.
Chaired by Professor Mingyi Chen (UT Southwestern Medical Center), the SAB is composed of distinguished members including Professor Zihai Li (Pelotonia Institute for Immuno-Oncology, The Ohio State University), Professor Weiping Zou (Michigan Center of Excellence for Cancer Immunology and Immunotherapy, University of Michigan), Professor Yang-Xin Fu (Shanghai Medical College of Fudan University), and Professor Pan-Chyr Yang (National Taiwan University College of Medicine). The SAB and HanchorBio’s leadership and R&D teams engaged in in-depth discussions on the company’s clinical programs, translational research, and AI-driven biomarker discovery strategy.
“It was a pleasure to participate in this productive SAB meeting and engage with the HanchorBio team on their scientific and clinical development plans,” said Professor Zihai Li, M.D., Ph.D., Founding Director of the Pelotonia Institute for Immuno-Oncology at The Ohio State University. “The scientific discussions during this SAB meeting were thoughtful, data-driven, and forward-looking. HanchorBio’s strategic approach to harnessing both innate and adaptive immunity through innovative immunotherapies, including CD47-SIRPα blockade, single molecule multi-targeted platforms, is highly compelling. I’m particularly encouraged by the company’s clinical progress with HCB101, with its differentiated high safety profile and potential in broad applications via combination strategies. The team’s exploration of new indications in oncology and autoimmune diseases and commitment to integrating AI-powered biomarker strategies to optimize patient selection and therapeutic outcomes demonstrates a clear vision to advance next-generation treatments for patients facing difficult-to-treat diseases.”
Key topics discussed included:
•Clinical Advancement of HCB101: Review of clinical data from the ongoing Phase 1 trial of HCB101, a best-in-class, engineered SIRPα fusion protein targeting CD47, as monotherapy and in combination with other standard-of-care across solid tumors.
•Strategic Expansion into Autoimmune Diseases: Scientific rationale for extending HCB101 development into B cell– and myeloid cell-driven autoimmune diseases, leveraging its myeloid-modulating mechanism to deplete autoreactive immune cells.
•Evaluation of New Oncology Indications: The SAB provided feedback on HanchorBio’s strategy to expand the development of HCB101 into an orphan drug designated for treating rare tumors with high unmet medical needs.
•Pipeline of Multi-Specific Immunotherapies: Presentation of HanchorBio’s proprietary multi-specific platforms, including HCB302 and bispecific molecules designed to overcome tumor immune resistance.
•AI-Driven Biomarker Platform: Introduction of HanchorBio’s innovative AI-based efficacy prediction platform, which utilizes patient-derived xenograft (PDX) models and transcriptomic analysis to develop gene expression signatures predictive of treatment response. The SAB provided valuable input on enhancing biological relevance, gene signature selection, and clinical validation strategies.
“We are grateful for the SAB’s expert insights and candid feedback, which will help us refine our scientific strategy and accelerate the development of our differentiated pipeline,” said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. “The SAB’s endorsement of our immuno-oncology programs, autoimmune disease exploration, and AI-driven biomarker efforts reinforces our commitment to delivering transformative therapies to patients worldwide. Importantly, our recent clinical progress, including the advancement of multiple combo-based Phase 1b/2a trials in triple-negative breast cancer and gastric cancer and the approval of investigator-initiated trials by the Taiwan Food and Drug Administration in advanced colorectal cancer and head and neck cancer, reflects the strong momentum of our rich clinical pipeline.”
HanchorBio plans to incorporate the SAB’s recommendations into its ongoing and future programs and looks forward to providing further updates on clinical progress, pipeline expansion, and AI-powered biomarker-driven precision medicine initiatives.
漢康生技，全球化的生物科技公司，致力於研發創新免疫生物藥，解決癌症及自體免疫疾病中重大的醫療需求，今日宣布近期於台灣台北成功召開第五屆半年一期的科學顧問委員會(Scientific Advisory Board, SAB)會議。此次會議邀集多位全球知名科學與臨床專家，共同就漢康生技目前的臨床前與臨床研發計畫，以及未來開發治療癌症與自體免疫疾病的新型多功能生物藥提供專業建議。
本次會議聚焦於癌症治療創新領域中的最新科學發展與產業趨勢，科學委員們提供寶貴的見解與建議，強化漢康生技的科學與臨床策略，推展其創新藥物開發，以滿足當前重大醫療的未竟之需。
科學顧問委員會由美國德州大學西南醫學中心的陳明義教授擔任主席，委員包括美國俄亥俄州立大學Pelotonia免疫腫瘤研究所李子海教授、美國密西根大學醫學院腫瘤免疫與免疫治療卓越中心主任鄒偉平教授、中國清華大學醫學院講席傅陽心教授，以及台灣大學醫學院內科楊泮池教授。科學委員們與漢康生技的管理和研發團隊針對臨床進程、轉譯研究與 AI 驅動生物標記發現的策略進行深度討論。
「很高興能參與這場高效的 SAB 會議，並與漢康團隊交流他們的科學與臨床發展計畫。」美國俄亥俄州立大學Pelotonia免疫腫瘤研究所李子海教授 (Zihai Li, PhD)表示：「本次討論深具前瞻性、數據導向，漢康尤其在創新免疫療法上的策略性布局，包括 CD47-SIRPα 阻斷與多特異性平台，來啟動先天性與適應性免疫方面的策略極具潛力。我對 公司在HCB101 的臨床進展，尤其是明顯的安全性與和應療法展現廣泛應用潛力感到振奮。團隊積極探索腫瘤與自體免疫新適應症，並整合 AI 驅動的生物標記(biomarker)策略來優化病患的篩選與療效，展現其推進次世代療法的展望。」
會議重點議題，包括：
• HCB101臨床進展：檢視HCB101，此同類最優(Best-in-Class)、針對 CD47 進行工程的 SIRPα 融合蛋白作為單一藥物與標準療法聯合使用於實體腫瘤中的第一期臨床數據。
• 戰略性拓展至自體免疫疾病：探討 HCB101 運用其影響髓系細胞機制以清除自體反應性免疫細胞的科學基礎，拓展至 B 細胞與髓系細胞主導的自體免疫疾病。
• 新腫瘤適應症評估： SAB 提供關於拓展 HCB101 至孤兒與罕見腫瘤領域的策略建議。
• 多特異性免疫療法研發進展：展現漢康生技專屬的多特異性平台，例如HCB302及雙特異性分子，用以克服腫瘤免疫抗性。
• AI 驅動的生物標記平台：介紹創新型 AI 療效預測平台，結合病患衍生異種移植模型(patient-derived xenograft, PDX)與轉錄體分析，以建立可預測療效的基因表現特徵。SAB 亦提供如何強化生物相關性、基因特徵選擇與臨床驗證策略的建議。
漢康生技創辦人、董事長暨執行長劉世高博士表示：「我們十分感謝SAB提供的專業洞見與真誠回饋，這將協助我們進一步優化科學策略，加速藥物開發的推進。SAB對我們在免疫腫瘤學、自體免疫與 AI 生物標記策略的肯定，加強了我們將為全球病患帶來轉型療法的信心。近期的臨床進展，包括多項針對三陰性乳癌與胃癌聯合療法的1b/2a試驗，以及台灣 TFDA 核准的轉移性大腸癌與頭頸癌研究者發起的臨床試驗(IIT)，展現我們臨床開發的強勁。」
漢康生技計畫將 SAB 的建議納入現行與未來的研發計畫中，並將持續更新有關臨床進展、藥物開發擴展與 AI 精準醫療計畫的最新消息。